$16.11
28.06% yesterday
Nasdaq, Dec 08, 10:15 pm CET
Why the stock moved Why the stock moved Beta
ISIN
US67576A1007
Symbol
OCUL

Ocular Therapeutix Inc Stock price

$16.11
+5.28 48.75% 1M
+7.21 81.01% 6M
+7.57 88.64% YTD
+6.76 72.30% 1Y
+13.35 483.70% 3Y
-3.35 17.21% 5Y
+6.75 72.12% 10Y
+2.96 22.51% 20Y
Nasdaq, Closing price Mon, Dec 08 2025
+3.53 28.06%
ISIN
US67576A1007
Symbol
OCUL
Industry

New AI Insights on Ocular Therapeutix Inc Insights AI Insights on Ocular Therapeutix Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$3.4b
Enterprise Value
$3.2b
Net debt
positive
Cash
$344.8m
Shares outstanding
175.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
61.5 | 61.1
EV/Sales
56.6 | 56.2
EV/FCF
negative
P/B
13.3
Financial Health
Equity Ratio
68.9%
Return on Equity
-61.4%
ROCE
-69.4%
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$55.8m | $56.2m
EBITDA
$-246.8m | $-272.5m
EBIT
$-250.8m | $-269.7m
Net Income
$-249.7m | $-260.8m
Free Cash Flow
$-199.4m
Growth (TTM | estimate)
Revenue
-9.2% | -11.9%
EBITDA
-79.5% | -62.2%
EBIT
-77.6% | -57.0%
Net Income
-43.2% | -34.8%
Free Cash Flow
-67.3%
Margin (TTM | estimate)
Gross
88.9%
EBITDA
-442.4% | -485.1%
EBIT
-449.7%
Net
-447.6% | -464.3%
Free Cash Flow
-357.5%
More
EPS
$-1.4
FCF per Share
$-1.1
Short interest
6.2%
Employees
274
Rev per Employee
$230.0k
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Ocular Therapeutix Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
95%
Hold
5%

Financial data from Ocular Therapeutix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
56 56
9% 9%
100%
- Direct Costs 6.21 6.21
7% 7%
11%
50 50
11% 11%
89%
- Selling and Administrative Expenses 113 113
20% 20%
203%
- Research and Development Expense 187 187
82% 82%
336%
-247 -247
80% 80%
-442%
- Depreciation and Amortization 4.03 4.03
6% 6%
7%
EBIT (Operating Income) EBIT -251 -251
78% 78%
-450%
Net Profit -250 -250
43% 43%
-448%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
4 days ago
BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under...
Neutral
Seeking Alpha
about one month ago
Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
about one month ago
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 274
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today